Stocks Health care NBP
NASDAQ · Health careNovaBridge Biosciences (NBP)
It posted a net loss of $46.3M. In fiscal 2025 capital spending exceeded operating cash flow by $20.6M. At December 31, 2025 it held $210.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on June 16, 2026.
What NovaBridge Biosciences does
NovaBridge Biosciences is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$46.3M | -$0.21 | -$20.6M |
| 2024 | n/a | -$22.2M | -$0.12 | -$52.7M |
| 2023 | $632K | -$207.7M | -$1.09 | -$184M |
| 2022 | -$1.6M | -$371.1M | -$1.96 | -$162M |
| 2021 | $13.8M | -$365.9M | -$2.09 | -$157.4M |
| 2020 | $236.4M | $72.2M | $0.46 | $65.2M |
Latest SEC filings
What NovaBridge Biosciences has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- September 8, 2026
- August 20, 2026
- August 20, 2026
- August 17, 2026
- July 24, 2026
- July 17, 2026
- June 29, 2026
- June 16, 2026Annual report (foreign issuer, amended) 20-F/A · period to December 31, 2025
- June 16, 2026
Questions about NBP
What does NovaBridge Biosciences do?
NovaBridge Biosciences is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NBP.
Is NovaBridge Biosciences profitable?
No. In fiscal 2025 it reported a net loss of $46.3M.
When did NovaBridge Biosciences last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on June 16, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from September 21, 2026.
Similar companies
Follow NBP
Get an email when NovaBridge Biosciences files with the SEC: results, executive changes, material agreements and annual reports.
Follow NBP: get an email when it filesWhere the numbers come from
Financial figures are the values NovaBridge Biosciences tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.